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Available online 26 December 2018Background: Even though liver kinase B1 (LKB1) is usually described as a tumor suppressor in a wide variety of
tissues, it has been shown that LKB1 aberrant expression is associated with bad prognosis in Hepatocellular
Carcinoma (HCC).
Methods: Herein we have overexpressed LKB1 in human hepatoma cells and by using histidine pull-down assay
we have investigated the role of the hypoxia-related post-translational modification of Small Ubiquitin-related
Modifier (SUMO)ylation in the regulation of LKB1 oncogenic role. Molecular modelling between LKB1 and its
interactors, involved in regulation of LKB1 nucleocytoplasmic shuttling and LKB1 activity,was performed. Finally,
high affinity SUMO binding entities-based technology were used to validate our findings in a pre-clinical mouse
model and in clinical HCC.
Findings:We found that in human hepatoma cells under hypoxic stress, LKB1 overexpression increases cell via-
bility and aggressiveness in association with changes in LKB1 cellular localization. Moreover, by using site-
directed mutagenesis, we have shown that LKB1 is SUMOylated by SUMO-2 at Lys178 hampering LKB1
nucleocytoplasmic shuttling and fueling hepatoma cell growth.Molecularmodellingof SUMOmodified LKB1 fur-
ther confirmed steric impedance between SUMOylated LKB1 and the STe20-RelatedADaptor cofactor (STRADα),
involved in LKB1 export from the nucleus. Finally, we provide evidence that endogenous LKB1 is modified by
SUMO in pre-clinical mouse models of HCC and clinical HCC, where LKB1 SUMOylation is higher in fast growing
tumors.
Interpretation: Overall, SUMO-2 modification of LKB1 at Lys178 mediates LKB1 cellular localization and its onco-
genic role in liver cancer.
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Liver Kinase B1 (LKB1) is a 50 kDa serine/threonine kinase ubiqui-
tously expressed in adult and fetal tissues, particularly in pancreas,
liver, testes and skeletal muscle [1]. LKB1 is an upstream activator of
14 kinases from the ARK (AMP-activated protein kinase-related kinase)
family including AMP-activated protein kinase (AMPK). In fact, the
defective activation of AMPK in LKB1-null cells can be rescued by re-
expression of LKB1 [2,3]. AMPK functions as a cellular energy sensor to
provide metabolic adaptations under ATP-deprived conditions such as
starvation and oxygen deprivation (hypoxia) [4]. Under these circum-
stances, AMPK activation results in stimulation of bioenergetic path-
ways and inhibition of ATP- and NADPH-consuming processes such as
biosynthesis and proliferation. It is particularly relevant in this respecth an ambiguous role in
tivity is augmented in
LKB1 cellular localiza-
n shown to be a target
UMO-mediated mod-
e in protein target sub-
on.
ession in human hepa-
tumor cell growth and
at endogenous LKB1
e models of HCC as
ally, our data suggest
cancer being essential
n and oncogenic role.
B1 SUMOylation as a
reby the putative ther-
and small molecule in-
s isoforms.that AMPK inhibits the mammalian target of rapamycin complex 1
(mTORC1) pathway [5] with concomitant downregulation of the glyco-
lytic pathway [6,7]. Indeed, silencing LKB1 in mouse embryonic fibro-
blasts promotes a metabolic switch to aerobic glycolysis, also called
the Warburg effect, a hallmark of highly proliferative tumor cells,
supported by mTOR activity and driven by hypoxia inducible factor
(HIF)-1α [8]. Moreover, AMPK can regulate energy expenditure by
modulating mitochondrial biogenesis and controlling the expression
of oxidative enzymes [9–11]. Alternatively, LKB1-induced activation of
AMPK signaling can offer a protective effect by allowing the cell time
to attempt to reverse the aberrantly high ratio of AMP/ATP, that other-
wise can cause cell death [12].
Germlinemutations or deletions in the LKB1 gene are responsible for
the Peutz-Jeghers Syndrome (PTS), a cancer-prone autosomal dominant
inherited disorder [1,13]. Likewise, somatic mutations of LKB1 gene are
involved in the development of sporadic cancers, such as cervical, pros-
tate and lung cancers, among others [14–16]. Although genetic evidence
supports the tumor-suppressive role for LKB1, other evidence revealed
that LKB1 may also exhibit pro-oncogenic functions. In the context of
liver disease, a controlled balance in hepatic LKB1 levels has been de-
scribed as a gatekeeper of hepatocyte proliferation during regeneration
[17,18]. Furthermore, LKB1 expression or activity have been previously
shown to be augmented in Hepatocellular Carcinoma (HCC), the most
common type of liver cancer, especially related to bad prognosis and
late stage HCC [19,20]. The mechanisms underlying the oncogenic role
of LKB1 in HCC remain rather unexplored.
LKB1 localizationwithin the cell is critical for the regulation of its ac-
tivity. LKB1 has a N-terminal regulatory domain in the most N-terminal
region after the kinase domain and a C-terminal regulatory domain [21].
LKB1 has also two specific recognition sequences called nuclear localiza-
tion sequences (NLS) in its N-terminal region [22], that allow the shut-
tling between cytoplasm and nucleus of LKB1 inmammalian cells. LKB1
nucleocytoplasmic shuttling is mediated by cofactors, such as the
STe20-Related ADaptor (STRADα) and mouse protein 25 (MO25) [2].
Briefly, STRADα induces relocalization of LKB1 from the nucleus to the
cytoplasm whereas MO25 stabilizes the STRADα-LKB1 interaction
[23,24]. On the other hand, STRADα inhibits nuclear import of LKB1
by competing with karyopherin importin-α for binding to LKB1 [25].
To date, several regulating mechanisms have been proposed to explain
LKB1 cellular localization: i) aberrant expression of STRADαwas associ-
ated with nuclear LKB1 during corticogenesis [26]; ii) the orphan nu-
clear receptor Nur77 can bind and sequester LKB1 in the nucleus [27];
and finally iii) reversible post-translational modifications of LKB1 have
been shown to regulate its stability and activity [19,28,29].
Post-translational modification is a critical event in the dynamic reg-
ulation of protein stability, location, structure, function, activity and
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scribed for the first time LKB1 Small Ubiquitin-related MOdifier
(SUMO)-mediated modifications and its implication under metabolic
stress circumstanceswhere SUMO-mediatedmodification of LKB1 is es-
sential in promoting its interaction with its downstream target AMPK
via a SUMO-interacting motif (SIM) essential for AMPK activation [29].
In addition, the SUMOproteinmodification has an extensive and critical
role in the adaptive cellular response to hypoxia [30–34]. Chronic hyp-
oxia is an importantmicro-environmental factor for establishing the ag-
gressiveness of HCC by promoting tumor invasion and metastasis
[35,36]. Thus, SUMOylation appears to be upregulated in many types
of cancer, including HCC [37–39]. Previously, expression of both the
SUMO E2 conjugating enzyme (Ubc9) and the E3 SUMO-protein ligase
CBX4 were found to be upregulated and related to poor prognosis in
HCC [38,39].
In this study, we aimed to explore the functional role of LKB1 in
hepatocarcinogenesis and progression with special focus on the role
played by SUMOylated LKB1 in themodulation of its cellular localization
in hepatoma cells during hypoxic stress and in liver cancer.
2. Materials and methods
2.1. Cell lines
Huh-7, Hep G2, and PLC/PRF/5, human hepatoma cell lines; and
MLP-29, mouse liver progenitor cells were used. All cells were grown
at 37 °C in a humidified atmosphere of 5% CO2–95% air and cultured in
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10%
FBS (Gibco, Thermo Fisher Scientific, Spain), unless otherwise stated.
2.2. Cell transfection
Cell lines were transiently transfected using Lipofectamine 2000
(Invitrogen, USA), according to the manufacturer's instructions. Briefly,
Lipofectamine 2000 (2.5 μl/1 μg DNA)was diluted in OPTI-MEM (Gibco)
medium for transfections and incubated for 5 min. After incubation, the
mixturewas added to OPTI-MEM containing plasmid DNA (1 to 6 μg de-
pending on the experiment), and incubated for at least 20 min at room
temperature (RT) to allow for the formation of the DNA-Lipofectamine
complexes. DNA-lipofectamine complexes previously formed were
added to the culture plates containing the corresponding culture me-
diumwith 10% FBS butwithout antibiotics andwith the cells in suspen-
sion. Plasmid DNA used are listed in Supplemental Table 1. Putative
SUMO sequence binding sites on LKB1 were analyzed using the
SUMOplot Analysis Program (http://www.abgent.com/SUMOplot,
Abgent, USA). The 4 highest ranking sites predicted by SUMOplot
were used to create the mutants (lysines 96, 97, 178 and 235). Lysines
were mutated to arginines (R). An additional acetylation LKB1 mutant
(K48R)was also created. Themutant LKB1 plasmid constructswere cre-
ated using the QuickChange kit for directed mutagenesis (Stratagene,
USA), according to the manufacturer's instructions, with two comple-
mentary oligonucleotides and with the pcDNA3-FLAG LKB1 plasmid as
a template. The products were sequenced (STABvida, Portugal).
2.3. Cell treatments
The selective inhibitor of sirtuin 1 (SIRT1), Ex-527 (Sigma-Aldrich)
in DMSO, was given to cells for 24 h at 30 μM. Cycloheximide, a eukary-
ote protein synthesis inhibitor was added to cells at 50 μg/ml in H2O.
2.4. Hypoxia in vitro
For hypoxia experiments, cells were incubated in an Invivo2 400
hypoxia Workstation (Baker Ruskinn, USA) at 1% O2 for until 72 h and
lysed/fixed in the hypoxia chamber.2.5. Serum deprivation in vitro
Cells were grownwithout FBS for a 24-hour period and compared to
cells maintained on 10%FBS.
2.6. Mouse models
All animal experiments were performed according to the ARRIVE
guidelines and carried out in accordance with the National Institutes
of Health guide for the care and use of Laboratory animals (NIH Publica-
tions N0.8023, revised 1978) and the guidelines of European Research
Council for animal care and use. Adult male C57BL/6 mice and mouse
models that develop HCC at 8-months old, such as the glycine N-
methyltransferase (Gnmt) deficient (Gnmt−/−) and wild type
(Gnmt+/+) mice, were bred and housed in the animal unit of CIC
bioGUNE, which is an AAALAC-accredited facility. Animals were housed
under controlled temperature (22 °C) and humidity conditions in a 12 h
light/dark cycle with ad libitum access to food and water.
2.7. In vivo hypoxia treatment
Three-month-old C57BL/6 mice males were exposed to systemic
hypoxia in a sealed workstation (Baker-Ruskinn InvivO2 400, Cultek).
The final 10% O2 environment was reached after a 2 h30 period in
which oxygen levels were gradually reduced. Feeding and light cycles
were kept uniform in the hypoxia workstation. Control mice were also
exposed to the same chamber but under a 21% O2 environment. Mice
were euthanized by cervical dislocation inside the chamber, and the dis-
sected organs were directly fixed.
2.8. Human HCC samples
The work described has been carried out in accordance with the
code of ethics of the World Medical Association (Declaration of Hel-
sinki) for experiments involving humans after obtaining informed con-
sent. Surgically resected liver specimens of 22 patients with HCC (10
Hepatitis C, 10 ASH and 2 NASH) were examined. The Basque Biobank
(http://www.biobancovasco.org) provided the data and type of
biospecimen. In addition, we have used frozen paired HCC tumor and
surrounding tissue liver biopsies obtained during tumor resection
(n = 6) as well as HCC liver biopsies from a set of samples previously
classified as fast growing (n = 3) or slow growing (n = 3). The latter
sampleswere included in a previously published larger study, which in-
cluded two cohorts of patients with cirrhosis of any etiology on ultra-
sound surveillance (training set = 78 and validation set = 54). At first
identification of HCC, they underwent two CT scans 6 weeks apart
with no treatment in-between. Fast growing patients has a median
tumor doubling time of 42 days while for the slow growing patient's
median tumor doubling timewas 97 days [40]. US-guided liver biopsies
were initially obtained and used to generate a microarray (Agilent
Whole Human Genome Oligo) according to the MIAME guidelines.
Gene expression data is available at the Gene Expression Omnibus
website (http://www.ncbi.nlm.nih.gov/geo) under the accession num-
ber: GSE54236.
2.9. Protein extraction and western blotting analysis
Protein extraction and Western blotting analysis was performed as
previously described [41]. Primary antibodies and their optimal incuba-
tion conditions are detailed in Supplemental Table 2.
2.10. Crystal violet viability assay
Cell viability was assessed using crystal violet staining (Sigma-
Aldrich).
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Cells were seeded to confluence over 12mm coverslip after an over-
night transfection. A pipette tip (200 μl) was used to scratch a straight
line through all the wells. Media was changed twice to remove dead
and unattached cells. The wells were then placed in hypoxia during
72 h. Pictures of the scratch were taken using an Eclipse TS100 micro-
scope (Nikon, Japan).
2.12. Subcellular proteome extraction kit
ProteoExtract® Subcellular Proteome Extraction Kit (S-PEK) from
Merck (Spain) was used.
2.13. Immunocytofluorescence
Cells seeded on 12 mm coverslips were fixed in PBS 4% paraformal-
dehyde (Santa Cruz Biotechnology, USA). Coverslips were then blocked
and permeabilized with PBS containing 0.1% BSA, 10% goat serum and
0·2% Triton X-100 for 30 min at RT. After blocking, the coverslips
were washed in PBS and incubated overnight in a humid chamber
with the primary antibody (FLAG 1:100) in PBS. Coverslips were
washed in PBS and incubated during 1 h at RT in blocking solution
with DAPI but no Triton X-100 with secondary antibody (dilution
1:200, Cy3 conjugated anti-mouse or FITC-conjugated anti-rabbit, Jack-
son ImmunoResearch laboratories, USA). Coverslips were mounted in
Dako fluorescence mounting medium (Dako, Denmark). Five Images
from each experimental condition were taken using an Axioimager D1
(Zeiss). Blind quantification of LKB1 positive nuclear cells versus total
number of stained cells was performed manually by an immunohisto-
chemistry technician.
2.14. Nickel-Histidine affinity purification using nickel-nitriolotriacetic acid
(Ni2+-NTA) beads
Cells were transfected with the respective constructs and His6-
SUMO as described. After treatments, His6-SUMOylated proteins were
purified as previously describedby using lowdensity Ni2+-NTA-agarose
beads (ABT, Spain) [19,42].
2.15. Protein immunoprecipitation assays
Total protein extracts were immunoprecipitated with 5 μg of IgG1
(BD Pharmigen), anti-LKB1 or anti-STRADα antibodies by using A/G
PLUS-Agarose Beads (Santa Cruz).
2.16. SUMO binding entities (SUBEs)
SUBEs, earlier described and validated [43], were used as a capturing
system for endogenous SUMOylated LKB1. Liver tissue (75 mg) from
Gnmt−/− and Gnmt+/+ aswell as fromHCC patients were used. Briefly,
livers were lysed in lysis buffer [50mMTris pH 8.5; 150mMNaCl, 5mM
EDTA, 1% Igepal, supplemented with 1× protease inhibitor cocktail
(Roche) and 50 μM of PR-619 (ubiquitin and ubiquitin-like
isopeptidases inhibitor, LifeSensors)]. Lysates were centrifuged at
14000 ×g and the supernatant was incubated with 50 μl of GST-
agarose beads containing 50 μg of SUBEs or GST and 1 mMDTT (Dithio-
threitol) for 2 h, at 4 °C. Beads were then pulled down by centrifugation,
1000×g for 5min, and 1/10 of the unbound fractionwas saved forwest-
ern blot analysis (flow through-FT). Washes were carried out using 30
column volumes of wash buffer (50 mM Tris pH 8.5; 50 mM NaCl,
5mMEDTA and 1% Igepal). Elutionswere performed in one columnvol-
ume of 2 Laemmli Buffer. For Western blot analysis, samples were sep-
arated in NUPAGE 4–12% BT Gels, 1.5 mm, 15Well.2.17. Modelling
Computational analysis of the various LKB1 species used the X-ray
diffraction coordinates of the LKB1-STRADα-MO25α complex by
Zequiraj et al. (2009; pdb 2WTK). Highly mobile regions of LKB1 were
absent and, therefore, needed modelling. For this purpose, 250 struc-
tures were generated using Modeller 9v7 [44] and classified according
to their Discrete Optimized Protein Energy (zDOPE) scores to select
the model with its lowest value. Molecular Dynamics trajectories were
computed with the AMBER 16 package [45], using the 14SB force field
[46]. For the acetylated lysine residue, Papamokos' parameterizations
[47] were used. Simulations run under periodic boundary conditions
in orthorhombic boxes. Initially, the minimum distance between pro-
tein and cell faces was 10 Å. PME electrostatics were set with the
Ewald summation cut-off at 9 Å. Sodium counter-ions neutralized the
charges of the system. The structures were solvated with SPC water
molecules [48]. Protein side-chains were energy-minimized (100
steepest descent and 1400 conjugate gradient steps) down to a RMS en-
ergy gradient of 0·01 kJmol-1 Å-1. Afterwards, solventwas subjected to
1000 steps of steepest descent minimization followed by 500 ps NPT-
MD computations using isotropic molecule position scaling and a pres-
sure relaxation time of 2 ps at 298 K. Temperature was regulated with
Berendsen's heat bath algorithm [49], with a coupling time constant
equal to 0·5 ps. The density of the system reached a plateau after ca.
150 ps simulation. Then, for each protein, the whole systemwas energy
minimized and submitted to NVT-MD at 298 K, using 2·0 fs integration
time steps. Snapshots were saved every 100 ps. SHAKE algorithm
(Ryckaert et al., 1977) was used to constrain bonds involving hydrogen
atoms. Coordinate fileswere processed using CPPTRAJ [50]. Further pro-
cessing was made in Origin 16 (Originlab) and graphic displays were
built in UCSF Chimera [51].
2.18. Immunohistochemistry
Paraffin-embedded sections (5 μm thick) of formalin-fixed liver
samples were initially deparafinized in xylene or xylene-substitute
and rehydrated through graded alcohol solutions. Specific antibodies
and experimental conditions used in immunohistochemistry can be
found in supplemental Table 3. For the analysis, images were taken
with an upright light microscope (Zeiss, Germany). The average sum
of intensities and stained area percentage of each samplewas calculated
using FRIDA software (http://bui3.win.ad.jhu.edu/frida/, John Hopkins
University).
2.19. Statistical analysis
Data is expressed as mean± SEM (standard error of themean). Sta-
tistical significance was estimated using the Mann-Whitney U test. A p
value of b0·05 was considered significant.
3. Results
3.1. LKB1 offers survival and invasiveness advantage to human hepatoma
cells during hypoxic stress
LKB1 is endogenously expressed in human hepatoma cells (Suppl.
Fig. 1a). These results are in agreement with earlier evidence showing
augmented expression of LKB1 in rodent hepatoma cells [52–54]. In
order to further explore the functional role of LKB1 in HCC progression,
we transiently overexpressed LKB1 in Huh-7 human hepatoma cells
both after serum deprivation (0% FBS) or under hypoxic (1% O2) condi-
tions in comparison with cells under normoxia (21% O2) and cultured
with 10% FBS. LKB1 ectopic transient overexpression in Huh-7 hepa-
toma cells results in comparable levels of LKB1 after 24 h of hypoxic,
serum deprivation or normoxic stimuli (Fig. 1a, Suppl. Fig. 1b).
Fig. 1. Liver Kinase B1 (LKB1) offers survival and invasiveness advantage to humanhepatoma cells during hypoxic stress. LKB1overexpressionwas induced in humanhepatomaHuh-7 cell
line by using the pcDNA3-FLAG-LKB1Wild Type plasmid (LKB1) and compared to control overnight transfection with the pcDNA™3.3-TOPO® plasmid (Ctrl), followed by 24 h treatment
under control conditions of normoxia and completemedia (21%oxygen, 10% serum), serumdeprivation (SD) and hypoxia (1% oxygen, 10% serum). a. RepresentativeWestern blot of LKB1,
its downstream target AMP-activated protein (AMPK) and phosphorylated AMPK at Thr172 and hypoxia inducible factor (HIF1α), a hypoxic marker, are shown. [β-actin was used as
loading control]. Quantifications are shown in Suppl. Fig. 1b; b. Cell viability as detected by staining of attached cells with crystal violet dye; c. Time-course of cell viability and cell
migration using a wound-healing scratch assay after LKB1 overexpression under hypoxia; d. Representative immunofluorescence staining for LKB1 (FLAG) in Huh-7 hepatoma cells
and quantification of the percentage of LKB1 nuclear positive staining cells. Scale bar corresponds to 50 μm; and e. Western blot of LKB1 levels in cytoplasmic and nuclear fractions
[Glyceraldehyde 3-phosphate (GAPDH) was used as loading control for cytoplasmic fractions and Histone H3 for nuclear fractions]. Quantifications are shown in Suppl. Fig. 1b. At least
triplicates were used per experimental condition. Data is shown as mean ± SEM. *p b 0·05 and **p b 0·01 are indicated (Mann-Whitney U test).
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Fig. 2. Liver Kinase B1 (LKB1) is SUMOylated by SUMO-2 in human hepatoma cells. a. Ni2+-NTA agarose bead pulldown inHuh-7 humanhepatoma cells after transfectionwithHis-SUMO-
1, 2, or 3,with thepcDNA3-FLAG-LKB1Wild type plasmid (LKB1WT) in thepresence and absence of ubiquitin conjugating enzyme9 (UBC9). b. Ni2+-NTA agarose bead pulldown inHuh-7
human hepatoma cells after transfection with His-SUMO-2 with the LKB1WT plasmid in the presence of the different SUMO E3 ligases PIAS 1, 2α, 2β, and 4. c. Ni2+-NTA agarose bead
pulldown in Huh-7 human hepatoma cells after transfection with His-SUMO-2 and with the LKB1 WT plasmid in the presence of the different SUMO-specific proteases, SENPs 1–7. d.
Ni2+-NTA agarose bead pulldown in Huh-7 human hepatoma cells after transfection with His-SUMO-2 and with the LKB1 WT plasmid or the pcDNA3-FLAG-LKB1 Kinase Dead K78I
plasmid. e. Immunoprecipitation assay between LKB1 and the STe20-Related ADaptor (STRADα) cofactor after STRADα overexpression in Huh-7 human hepatoma cells. Normalized
quantifications relative to inputs are shown below the panel.
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Fig. 3. Liver Kinase B1 (LKB1) is SUMOylated by SUMO-2 at Lys178 in human hepatoma cells. a. Schematic representation of LKB1 showing the Nuclear (NLS) localization and the Kinase
domain (KDN). SUMOylation LKB1mutants used are also shown and described. b. Ni2+-NTA agarose bead pulldown in Huh-7 human hepatoma cells after transfection with His-SUMO-2
and the LKB1 SUMOmutants, LKB1 K96R, LKB1 K97R, LKB1 K178R and LKB1 K235R. Normalized quantifications relative to inputs are shown below each panel.
412 I. Zubiete-Franco et al. / EBioMedicine 40 (2019) 406–421LKB1 is an upstream activator of AMPK promoting the phosphorylation
of AMPK Thr-172 in the activation loop of its α subunit in response to
metabolic stress in order to inhibit biosynthesis and proliferation [2,3].
Herein, LKB1 overexpression increased phosphorylation of AMPK at
Thr-172 except during hypoxic stress, a condition characterized by
high HIF-1α levels (Fig. 1b, Suppl. Fig. 1b). Interestingly, after 24 h of
hypoxia, LKB1 upregulation was associated with increased cell viability
in comparison with control and serum deprived cells, both in Huh-7
(Fig. 1b) and another cell line of mouse liver progenitor cells, the
MLP-29 cells (Suppl. Fig. 2a). A time course indicates that whereas hep-
atoma cells growth is hampered during hypoxia, LKB1 overexpression is
able to induce cell growth under these conditions (Fig. 1c). Further-
more, hypoxia is known to unleash the invasive potential of tumor
cells. Scratch wound-healing assay revealed that LKB1 overexpression
also provides and invasiveness advantage to tumor cells under hypoxia
(Fig. 1c).LKB1 cellular localization plays an important role its activity. During
serum deprivation and normoxia conditions LKB1 actively shuttles be-
tween the nucleus and cytoplasm whereas under hypoxia, the LKB1
nucleocytoplasmic shuttling is hampered and LKB1 is more present in
the nucleus (Fig. 1d, e, Suppl. Fig. 1c).
Overall, LKB1 overexpression provides growth survival and inva-
siveness advantage to hepatoma cells during hypoxic stress which
agrees with previous evidence from our laboratory and others showing
that LKB1 expression is induced in HCC tumors [19,20], tumors charac-
terized by a highly hypoxic environment.
3.2. Increased LKB1 SUMOylation in human hepatoma cells
As previously mentioned, SUMOylation post-translational modifica-
tions are critical during hypoxia and thereby relevant in HCC [38,39]. In
mammals, there are five SUMO paralogues, being SUMO-1, -2 and -3
Fig. 4. Liver Kinase B1 (LKB1) SUMOylation at Lys178 by SUMO-2 regulates human hepatoma cell survival by hampering LKB1 nucleocytoplasmic shuttling. LKB1 overexpression was
induced in Huh-7 cells with pcDNA3-FLAG-LKB1 Wild Type plasmid (LKB1 WT) or the pcDNA3-FLAG-LKB1 K178R plasmid (LKB1 K178R) in the presence of His-SUMO-2. a. Western
blot analysis of LKB1, [Glyceraldehyde 3-phosphate (GAPDH) was used as loading control]. Quantifications are shown in Suppl. Fig. 4a; b and c. Cell viability as detected by staining of
attached cells with crystal violet dye and number of cells; d. Immunoprecipitation assay between LKB1 WT and LKB1 K178R and the STe20-Related ADaptor (STRADα) cofactor after
STRADα overexpression in Huh-7 human hepatoma cells. Normalized quantifications relative to inputs are shown below the panel; e. Representative immunofluorescence staining for
LKB1 (FLAG) in Huh-7 cells and quantification of the percentage of LKB1 nuclear positive staining cells. Scale bar corresponds to 50 μm. f. LKB1 levels in cytoplasmic (Cyto) and nuclear
fractions (Nuc) [Glyceraldehyde 3-phosphate (GAPDH) was used as loading control for cytoplasmic fractions and Histone H3 for nuclear fractions]. Quantifications are shown in Suppl.
Fig. 4b. At least triplicates were used per experimental condition. Data is shown as mean ± SEM. *p b 0·05 is indicated (Mann-Whitney U test).
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protein levels are low, on the contrary to other tissues such as lung,
uterus and prostate, whereas SUMO-2/3 levels in the liver are high
[58]. On this regard, we have found that mice exposed to hypoxia
show increased liver LKB1 nuclear expression and SUMO-2/3 levels
(Suppl. Fig. 3a). Furthermore, we show that endogenous LKB1
SUMOylation by SUMO-2/3 is induced in Huh-7 hepatoma cells after
24 h of hypoxia in comparison with cells grown under normoxic condi-
tions (Suppl. Fig. 3b). To further explore the role of SUMO-mediated
modifications of LKB1 in hepatoma cells, Ni2+-NTA agarose bead-pulldowns were performed in Huh-7 human hepatoma cells after co-
transfection of pcDNA3-FLAG-LKB1 wild type (WT) and pcDNA3-His6-
SUMO1, pcDNA3-His6-SUMO2 or pcDNA3-His6-SUMO3 plasmids. Our
results show that LKB1 is mostly modified by SUMO-2, in a SUMO-
conjugating enzyme UBC9 dependent process, both in Huh-7 human
hepatoma cells (Fig. 2a) and in MLP-29 cells (Suppl. Fig. 4a). Co-
transfection with the E3 SUMO-protein ligases PIAS, especially PIAS 1,
further increased LKB1 SUMOylation by SUMO-2 in Hu7–7 cells
whereas co-transfection with SUMO-specific proteases, particularly
SENP2, and SENP-1 and -3, decreased LKB1 SUMOylation (Fig. 2b,c). In
Fig. 5. Liver Kinase B1 (LKB1) is modified by SUMO-2 in Lys178 after its acetylation at Lys48 in human hepatoma cells. a. Schematic representation of LKB1 showing the Nuclear (NLS)
localization, acetylation domain (AD) and the Kinase domain (KDN). Acetylation LKB1 mutant used is shown. b. Ni2+-NTA agarose bead pulldown in Huh-7 human hepatoma cells
after transfection with the pcDNA3-FLAG-LKB1 Wild type plasmid (LKB1 WT), His-SUMO-2 and treatment with sirtuin 1 (SIRT1). c. Ni2+-NTA agarose bead pulldown in Huh-7 human
hepatoma cells after transfection the LKB1 WT, LKB1 acetylation mutant, LKB1 K48R or the LKB1 SUMOylation mutant, LKB1 K178R, with His-SUMO-2, in the presence and absence of
the Ex-527, the SIRT1 inhibitor. Normalized quantifications relative to inputs are shown below each panel; d. Representative immunofluorescence staining for FLAG and
quantifications in Huh-7 hepatoma cells after transfection with the LKB1 WT or the LKB1 SUMOylation mutant LKB1 K178R and SUMO-2 in the presence and absence of Ex-527. Scale
bar corresponds to 50 μm. At least triplicates were used per experimental condition. Data is shown as mean ± SEM. *p b 0·05 and **p b 0·01 are indicated (Mann-Whitney U test).
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the control of HCC cell growth [59]. The SUMOylation of LKB1 does not
depend on LKB1 kinase activity domain as a kinase dead (KD) mutant,
pcDNA3-FLAG-LKB1 K78I, was equally modified by SUMO-2(Fig. 2d e). Finally, SUMO-2-mediated modification of LKB1 reduced
the interaction between LKB1 and STRADα, a co-factor involved in
LKB1 nuclear export, as shown by immunoprecipitation assay, during
STRADα overexpression (Fig. 2e).
Fig. 6.Model of structural and dynamic changes on Liver Kinase B1 (LKB1) upon post-translational changes. a. Structure of LKB1 in the context of its ternary complex with STRADα and
MO25 [80] (pdb code: 2WTJ). Residues of LKB1 closerwithin 6Å of either STRADα orMo25 are in yellow, those closer than 4 Å are in orange.MO25 interactswith LKB1 through theA-loop,
while STRADα interacts with the β2-β3 loop and the CFTL region. b. Comparison of the structures along the molecular dynamics computations. The Root Mean Square Deviation of
trajectory snapshots upon alignment to the initial, energy minimized structure. Upper: data corresponding to unmodified LKB1 is in dark cyan, and that of K178-SUMOylated LKB1 is
in blue. Lower: the trajectory of K48-acetylated LKB1 is in ochre, and dark red dots represent that computed for the K48-acetylated and K178-sumoylated. c. Per-residue atomic
fluctuations computed along the last 250 ns of the trajectories. Colour attributes in b apply also to this panel. d. Map of changes in atomic fluctuations between unmodified LKB1 and
fully modified (ALY at position 48, SUMO at position 178) onto the model obtained by simulated annealing of the mobile parts of LKB1 using the 2WTJ coordinates. Residues in red are
more mobile in the unmodified protein, those in blue are more mobile in the fully modified one. e. Overlay of the structures of unmodified (cyan) and fully modified (red; SUMO in
yellow) LKB1. Ribbons represent the coordinates closest to averages of the analyzed trajectory intervals. f. Detail of the terminal part of the CFTL region of the acetylated and
SUMOylated STK domain of LKB1, according to the structure closest to the average of the last 250 ns of MD computations.
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By using the SUMOplot™ (http://www.abgent.com/sumoplot) and
JASSA Analysis Programs [60] to predict and score the potential
SUMOylation sites in LKB1, we found that LKB1 contains 3 high scoring
sites for possible SUMO binding sites in its amino acid sequence
(Fig. 3a). By using site-directed mutagenesis we created LKB1 arginine
mutants of the 3 highest scoring SUMO binding sites. Transfection of
human hepatoma Huh-7 (Fig. 3b) and MLP-29 (Suppl. Fig. 4b) cells
with pcDNA3-His6-SUMO2 and the different mutants showed that
LKB1 is mostly SUMOylated by SUMO-2 at Lys178. In spite of this,
other physiological or pathological relevant LKB1 SUMO-binding lysines
in LKB1 cannot be excluded. Even though the LKB1 SUMOylation mu-
tant at lysine 178 has been previously shown to display catalytic activity
[29], the potential role of SUMO-2 mediated modification at Lys178 of
LKB1 on this protein nucleocytoplasmic shuttling in hepatoma cell has
not been addressed.3.4. LKB1 SUMOylation at Lys178 by SUMO-2 regulates human hepatoma
cell survival by hampering LKB1 nucleocytoplasmic shuttling
As previously observed under hypoxic stress, transfection with the
LKB1 wild type plasmid in the presence of SUMO-2, increased human
hepatoma cell survival. On the other hand, transfection with the LKB1
SUMOylation mutant at Lys178 (pcDNA3-FLAG-LKB1 K178R) under
the same conditions did not account for increased tumor cell viability
(Fig. 4a–c, Suppl. Fig. 5a). Cycloheximide Chase Assay confirmed that
protein stability between pcDNA3-FLAG-LKB1 wild type (WT) and
pcDNA3-FLAG-LKB1 K178R proteins is similar (Suppl. Fig. 6a). Inaddition, LKB1 mediated SUMO-2 modifications promoted the loss of
the ability of LKB1 to bind to STRADα, whereas pcDNA3-FLAG-LKB1
K178R shows higher affinity for STRADα (Fig. 4d). Finally, transfection
of human hepatoma cells with the pcDNA3-FLAG-LKB1WT in the pres-
ence of pcDNA3-His6-SUMO2 induced LKB1 nuclear retention contrary
to what occurs with the SUMOylation mutant (Fig. 4e,f, Suppl. Fig. 5b).
Transfection of human hepatoma cells with either the pcDNA3-FLAG-
LKB1 WT plasmid and with the SUMOylation mutant LKB1 K178R,
that is not able to interactwith AMPKandphosphorylate it as previously
shown [29], show reduced phosphorylation of AMPK (data not shown).
Overall, LKB1 SUMOylation at Lys178 by SUMO-2 regulates cell
growth in human hepatoma cells by hampering LKB1 interaction with
STRADα and thereby its nucleocytoplasmic shuttling.
3.5. LKB1 SUMO-2 modification at Lys178 is favored by its acetylation
at Lys48 in human hepatoma cells
Crosstalk between SUMOylation and acetylation pathways is crucial
for the regulation of protein activity. On this basis, LKB1 has been previ-
ously shown to be acetylated at Lys48 [61]. Importantly, we observed
that SIRT1 overexpression, a NAD dependent sirtuin that deacetylates
LKB1 at the key acetylation Lys48, as well as transfection with the
LKB1 acetylation mutant, pcDNA3-FLAG-LKB1 K48R, both precluding
LKB1 acetylation, reduced LKB1 SUMOylation by SUMO-2. Of notice,
pcDNA3-FLAG-LKB1 K48R stability is similar to the WT plasmid
(Suppl. Fig. 6b). On the other hand, treatment with Ex-527, a SIRT1 in-
hibitor [62] increasing LKB1 acetylation, significantly augmented LKB1
SUMOylation by SUMO-2 (Fig. 5a–c).
LKB1 acetylation at Lys48 has been previously shown to prevent
LKB1 binding to STRADα hampering LKB1 nucleocytoplasmic export
Fig. 7. Liver Kinase B1 (LKB1) is modified by SUMO-2 in mouse models of Hepatocellular Carcinoma (HCC). a. Representative immunohistochemical analysis and quantification of LKB1,
SUMO-2/3 and HIF1α staining. Scale bar corresponds to 50 μm;At least 5 animals per groupwere used; b.Western blot analysis and quantification of LKB1 by using SUMObinding entities
(SUBEs) to capture endogenous SUMOylated LKB1; and c. Immunoprecipitation assay and quantification for SUMO-2 and LKB1 in tumor and non-tumor livers of wild type and Glycine-N-
methyltransferase (Gnmt−/−) HCC mice. Three animals per group are shown. Data is shown as mean ± SEM. *p b 0·05 is indicated (Mann-Whitney U test).
416 I. Zubiete-Franco et al. / EBioMedicine 40 (2019) 406–421[61]. In spite of this, in our in vitro model of human hepatoma cells,
treatment with Ex-527, which accounts for increased LKB1 acetylation
and promoting LKB1 SUMOylation, further boosts LKB1 nuclear accu-
mulation, whereas on the other hand, transfection with LKB1 K178R
SUMOylation mutant, localizes LKB1 to the cytoplasm independent ofthe LKB1 acetylation status (Fig. 5d,e). These results suggest that in
human hepatoma cells, LKB1 is mostly modified by SUMO-2 in Lys178
after its acetylation at Lys48, and that SUMOylation of acetylated LKB1
plays an important role in hampering LKB1 nucleocytoplasmic
shuttling.
Fig. 8. LKB1 SUMOylation in clinical HCC is associated with aggressiveness of the tumor. a. Representative immunohistochemical analysis and quantification of LKB1 and SUMO-2/3
staining in clinical HCC patients (n = 22) and healthy controls (n = 5). Scale bar corresponds to 50 μm. b. Western blot analysis and quantification of LKB1 by using SUMO binding
entities (SUBEs) to capture endogenous SUMOylated LKB1 in liver biopsies of HCC patients comparing the tumor with the surrounding tissue. 5 paired samples were used.
Surrounding tissue (ST) and tumor (T). c. Volcano plot of gene expression of the main genes involved in SUMO pathway, hypoxia and hypoxia responsiveness genes retrieved from a
previous published microarray where HCC patients were separated into more aggressive and less aggressive HCC, according to the tumor doubling time and survival [40]; d.
Representative LKB1 staining in more aggressive and less aggressive HCC tumors. Scale bar corresponds to 50 μm. e. Western blot analysis and quantification of LKB1 by using SUBEs
to capture endogenous SUMOylated LKB1 in liver biopsies of HCC patients classified as more aggressive or less aggressive tumors (3 samples each were used for less aggressive and
more aggressive tumors). Data is shown as mean ± SEM. *p b 0·05 is indicated (Mann-Whitney U test).
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Several regions of the LKB1 STKdomain interact with either STRADα
or MO25 (Fig. 6a). Assessing the effects of post-translational modifica-
tions on the affinity LKB1 towards their partners required to analyze
their effect on the structure and in particular, the above regions. How-
ever, several loop and mobile regions in LKB1 were missing in the set
of coordinates. Modelling them by simulated annealing provided a rea-
sonable model from a total of 250 structures (zDOPE b−1). This model
was used in four molecular dynamics (MD) computations. Twosimulations aided to assess the behavior of the STK domain in the ab-
sence of acetylation. The first one corresponded to unmodified STK do-
main; the second, to the domain SUMOylated at Lys 178. Another pair of
simulations were computed upon acetylation of Lys 48: with and with-
out SUMOylation at Lys 178. Fig. 6b displays the time course of the root
mean square deviations (RMSD) for the core of the STK domain along
the trajectories, taking the energy-minimized structures as reference.
None of the proteins showed substantial changes along the trajectories,
being stable along the 300 ns computed. However, SUMOylated pro-
teins displayed lower RMSD values, probably because the SUMO adduct
damps the motions of nearby regions of the STK domain. The N- and
Fig. 9. SUMOylation regulates Liver Kinase B1 (LKB1) nucleocytoplasmic shuttling and its oncogenic potential in liver cancer. LKB1 acetylation at Lys48 and posterior SUMOylation at
Lys178 by SUMO-2 account for the nuclear retention of LKB1 in liver cancer by hampering the binding of LKB1 to STRADα.
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this analysis, for a better assessment of atomic fluctuations (Fig. 6c,d).
The RMSF patterns indicate that both C- and N-terminus are highly flex-
ible (Fig. 6c). In addition, several sequence stretches display enhanced
fluctuations. Among them stand out the β2-β3 loop (residues 68–73),
theA-loop (201–208), the EF-αF loop (226–230), the C-lobe and the ad-
jacent α-helix (255–277), as well as the C-terminal Flanking Tail (CFTL,
314–347) and the C-terminus. Differences in mobility between the un-
modified and the double modified (K48-acetylated and K178-
SUMOylated) protein are further illustrated (Fig. 6d). Both, acetylation
and SUMOylation restrain the mobility of most of these regions
(Fig. 6c,d). Notably, acetylation of K48 induces a decrease in themobility
of the A-loop and the C-lobe, which lay far from this residue, similar to
the effect of SUMO attachment. This suggests a concertation of the
N-terminus motions with those in regions that will neighbor the
SUMO moiety. The conformational entropy loss due to acetylation
could favor SUMOylation, probably providing a pre-pay for the entropy
loss intrinsic to the SUMOylated LKB1 species.
The overall structure of the STK domain of LKB1 barely changes
along the four trajectories, according to the low RMSD values (Fig. 6e).
However, substantial differences are observable at various loops and
flexible regions. The most significant ones map at the A-loop, the αEF-
αF loop (residues 226–233), the C-lobe and a region of the CFT spanning
from residues 328 to 339, shown in Fig. 6f. Notably, this region com-
prises two targets for phosphorylation (S334 and T336), besides beinginvolved in the interaction with STRADα. Additionally, this sequence
stretch locates within an element (331RWRSMTVVPYL343) known to be
a target of 14–3-3ζ [63].
In summary, both K48 acetylation and K178 SUMOylation affect
both, the structure and the dynamics of several regions involved in
binding STRADα, thereby providing a rationale for the biological effects
observed related to LKB1 nucleocytoplasmic shuttling.
3.7. LKB1 is modified by SUMO-2 in mouse models of Hepatocellular
Carcinoma
Mice deficient in Glycine-N-methyltransferase (Gnmt) spontane-
ously develop steatosis at 3 months of age, HCC early foci at 6 months
old and multifocal HCC around 8 months of age [64]. Eight-month old
Gnmt−/− mice show higher staining area for LKB1 (highly nuclear),
SUMO-2/3 and the HIF-1α hypoxic marker that their wild-type litter-
mates (Fig. 7a). In these animals, by using by using high affinity SUMO
binding entities (SUBEs)-based technology [43], traps that can only
recognize endogenous SUMOylated proteins and do not bind to any
other member of the ubiquitin family we show that augmented
polySUMOylated species of LKB1 are found in theGnmt−/− liver tumors
(Fig. 7b). Likewise, an immunoprecipitation assay revealed that LKB1 is
mostly modified by SUMO-2 in the Gnmt−/−mice bearing liver tumors
(Fig. 7c). In summary, these data highlight that LKB1 is modified by
SUMO-2 in pre-clinical mouse models of HCC.
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Herein, we have evaluated LKB1 and SUMO-2/3 levels in HCC biop-
sies. Our results show that LKB1 levels are induced as well as SUMO-2/
3 expression in HCC in comparison to healthy controls (Fig. 8a). Also,
by using SUBEswe show that LKB1 ismore SUMOylated in the tumor re-
gion versus the surrounding tissue (Fig. 8b).We havemoved far beyond
and have analyzed the role of SUMOylation in HCC survival. To address
this, we have used a previously published microarray study comparing
the expression of genes both in aggressive and less aggressive tumors
[40]. The majority of SUMOylation related genes, as well as hypoxia
and hypoxia responsiveness genes are significantly augmented in pa-
tients showing worst survival, with more aggressive tumors (Fig. 8b).
These results are in agreement with earlier evidence showing that the
hypoxia-inducible factors HIFs are master regulators of angiogenesis
[65] and neoagiogenesis-related genes are hallmarks of fast-growing
HCC [40]. In agreement, analysis of the gene array retrieved that
SUMO-2, PIAS-1 and SENP-3 are significantly augmented in more ag-
gressive HCC, in agreement with our data in human hepatoma cells
showing that LKB1 SUMOylation at Lys 178 is mostly regulated by
PIAS-1 and SENP-3 activities. Also, in representative paraffin sections
of these two groups of patients,we have observed that LKB1 is highly lo-
calized in the nucleus of more aggressive tumors (Fig. 8c). Finally, by
using SUBEs we show that the levels of SUMOylated LKB1 are induced
in more aggressive HCC tumors (Fig. 8d).
In summary, these data highlighting that LKB1 ismodified by SUMO-
2 in clinical HCC tumors further supports a potential role for LKB1
SUMOylation as a novel oncogenic mechanism in a subtype of HCC
patients.4. Discussion
LKB1 is usually considered a tumor suppressor in a wide variety of
tissues once the hereditary and somatic loss of function mutations of
this gene are associated with an increased risk of cancer development
[1,13–16]. However, in HCC, one of themost frequentmalignant tumors
and an important cause of cancer death, only sporadically genetic alter-
ations of the LKB1 gene together with one LKB1missense mutation and
allelic loss were identified [66]. In fact, previous findings from our group
and others have shown that LKB1 levels are high inHCC, especially in as-
sociation with bad prognosis, and showing increased activation of
LKB1 at late stages of the disease [19,20,52]. In agreement, in xenograft
orthotopic tumors in severe combined immunodeficiency (SCID) mice,
LKB1 suppression decreased tumor growth [52]. The role for LKB1 as
an oncogenic driver in HCC hepatocarcinogenesis and progression is
therefore controversial on the light of current literature.
LKB1 is an upstream activator of AMPK. Indeed, lack of LKB1 is usu-
ally associated with inactivation of AMPK and deregulated cell growth
[67,68] whereas activation of LKB1 inhibits the proliferation of many
different tumor cell types [69]. Most of the current analysis of LKB1
function has focused on its regulation of AMPK and mTOR signaling.
Failure of AMPK phosphorylation by LKB1-deficient cells exhibit
hyperactivated mTORC1 and elevated HIF signaling which in turn stim-
ulates aerobic glycolysis and lowers oxidative phosphorylation depen-
dence inducing deregulated cell proliferation [7]. In alternative,
suppression of LKB1 leads to apoptosis in cell lines where Akt is consti-
tutively active suggesting that LKB1 is necessary for Akt-mediated phos-
phorylation of proapoptotic proteins [70]. Regarding HCC, we have
previously shown that LKB1 is essential for liver tumor pathogenesis
in themethionine adenosyltransferase A1 (Mat1A−/−)HCCmice by reg-
ulating Akt-mediated survival independent of PI3K, AMPK andmTORC2
[53]. In here, we have moved far beyond and showed that LKB1 overex-
pression in human hepatoma cells is associated with increased cell via-
bility and invasiveness during hypoxic stress, an important signature of
more aggressive HCC [38,39]. Whether under hypoxia LKB1 offersgrowth advantage to hepatoma cells or accounts for increased survival
needs to be further investigated.
The activity of LKB1 is tightly controlled by its cellular localization, a
process that relies on the binding of LKB1 to STRADα and stabilization
by MO25 [23,24]. We have observed that LKB1 overexpression in hepa-
toma cells and concomitant increased cell viability during hypoxia is as-
sociated with failure of LKB1 binding to STRADα and its retention in the
nuclear region. Post-translational modifications of LKB1 play an impor-
tant role on the assembly of the LKB1/STRADα complex and therefore
may regulate LKB1 nucleocytoplasmic shuttling. For example, the phos-
phorylation of LKB1 at serine 428 was previously shown to induce the
nuclear export of LKB1 and activation of AMPK in endothelial cells
[71,72]. On the other hand, inmelanoma cells transformedbymutations
of oncogenic B-Raf kinase, LKB1 becomes phosphorylated at two sites
that compromise the ability of this enzyme to bind an phosphorylate
AMPK [73]. LKB1 has also been shown to be a neddylation target in
HCC, a post-translational modification that increases LKB1 stability
through the covalent binding of the ubiquitin-like molecule Nedd8
[19]. Loss of LKB1 farnesylation in mice results in decreased AMPK acti-
vation by promoting the interaction and co-localization of these two en-
zymes at the plasma membrane [28]. In alternative, both LKB1
acetylation [61] and the K63-linked LKB1 polyubiquitination by Skp2-
SCF ubiquitin ligase [20] have been shown to be critical for LKB1 activa-
tion by maintaining the LKB1-STRADα-MO25 complex. More recently,
Ritho and colleagues have described that energy stress triggers an in-
crease in the modification of LKB1 by SUMO-1 at lysine 178, being this
modification essential in promoting LKB1-AMPK interaction whereas
absence of SUMOylation is associatedwith defective AMPK signaling in-
ducing apoptosis in starved cells [29].
In this study, we have shown for the first time that SUMO-2 modifi-
cations of LKB1 at Lys178 occur in human hepatoma cells during hyp-
oxia hindering the LKB1 nucleocytoplasmic shuttling by hampering
the LKB1/STRADα binding. These set of evidence were further sup-
ported by molecular modelling data. In hepatoma cells, SUMO-1 medi-
ated modifications of LKB1 were not detected, being SUMO-2
mediated modifications of LKB1 prevalent. This may be related to the
fact that SUMO-1 levels are low in liver whereas SUMO-2/3 levels are
high, on the contrary to other tissues such as lung and prostate [58].
Modifications of LKB1 by different paralogues of SUMOmay play differ-
ent roles as for example SUMO-1 acts as a chain terminator on SUMO-2/
3 polymers [74] whereas polymeric SUMO chain formation is particu-
larly relevant in the regulation of the subcellular localization of its sub-
strate proteins [75]. Importantly, we show that LKB1 SUMOylation was
augmented both in pre-clinical mousemodels of HCC as well as inmore
aggressive HCC clinical tumors.
Herein we also describe that LKB1 acetylation at Lys48 is essential
for its posterior SUMOylation by SUMO-2 at Lys178 in hepatoma cells.
However, we provide evidence that even under circumstances where
LKB1 is acetylated, as after the treatment with Ex-527, the SIRT1 inhib-
itor, failure of LKB1 SUMOylation at Lys178 promotes LKB1 cytoplasmic
localization. These results suggest that LKB1 SUMOylation and not its
acetylation is themain player in the regulation of LKB1 cellular shuttling
in human hepatoma cells.
In the last years, LKB1 has been shown to function both in the cyto-
plasm and nucleus. The presence of LKB1 in the nucleus during liver can-
cer described in here can explain how LKB1 fails to activate cytoplasmic
AMPK and induce tumor cell growth and invasiveness potential in a
tumor hypoxic environment. Likewise, cancer invasion is impeded
whenSTRADα is depleted andenhancedwhenSTRADα is overexpressed
[76]. Thus, the observed increased invasiveness as a result of LKB1 over-
expression in hepatoma cells can also be a direct result of lack of associa-
tion between STRADα and LKB1. Finally, the nuclear role for LKB1 during
hypoxia in hepatoma cells and liver tumors is not fully understood and
appears to be crucial. Although LKB1 was previously shown to bind and
stabilize p53 in the nucleus, arresting cell cycle and promoting apoptosis
in some types of cells [77], p53 is not required for induction of apoptosis
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present in the nucleus, LKB1 is able to interact, through its SUMO-2 poly-
meric chains, with other proteins containing SUMO-interaction motifs
and DNA binding domains. On this basis, we previously reported that
LKB1 is able to activate the oncogenic pathway of RAS through the ex-
pressionof RAS guanyl releasing protein-3 (RASGRP3) [52]. Interestingly,
RasGRP3was shown to be localized in the cytoplasmof the cells whereas
the active form exhibited mostly nuclear immunoreactivity [79]. Based
on our premises, nuclear LKB1 could attach to the promoter region of
RasGRP3 as well as to other intermediates of oncogenic pathways in-
creasing its expression and related Ras oncogenic activity, at least under
hypoxic conditions. Chronic Ras activation can alternatively promote
the Skp-2-mediated joint polyubiquitination of Lys48 and other lysines,
and regulate LKB1activity bymaintaining LKB1-STRADα-MO25 complex
integrity thereby increasing the activation of LKB1 observed at late HCC
[20]. Further studies are necessary in order to identify possible binding
nuclear LKB1 interactors present in hypoxic liver tumors.
In summary, we propose that LKB1 SUMOylation by SUMO-2 offers
an alternative mechanism for hampering the binding of LKB1 to
STRADα, possibly due to some type of steric hindrance. LKB1
SUMOylation promotes the nuclear sequestering of LKB1 and concomi-
tant hepatoma cell growth and invasiveness advantage in hypoxic HCC
tumors (Fig. 9). On this basis, we can hypothesize that first of all SUMO-
2-mediated LKB1 modifications may account for the rather unique role
of LKB1 as an oncogenic driver in liver cancer and secondly speculate
about the valuable therapeutic potential for some subtypes of HCC of
protein-based, peptidyl and small molecule inhibitors of various
SUMO specific proteases isoforms.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.12.031.
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